SNGX | Soligenix, Inc.

Index- P/E- EPS (ttm)-3.65 Insider Own0.36% Shs Outstand8.12M Perf Week2.04%
Market Cap5.96M Forward P/E- EPS next Y-1.74 Insider Trans0.00% Shs Float8.11M Perf Month-32.75%
Income-10.50M PEG- EPS next Q-0.49 Inst Own7.30% Short Float / Ratio4.32% / 0.40 Perf Quarter-74.75%
Sales1.00M P/S5.96 EPS this Y-2.40% Inst Trans-13.14% Short Interest0.35M Perf Half Y-91.19%
Book/sh-1.16 P/B- EPS next Y15.10% ROA-64.90% Target Price29.88 Perf Year-90.36%
Cash/sh1.28 P/C0.58 EPS next 5Y1.00% ROE- 52W Range0.65 - 15.00 Perf YTD-89.09%
Dividend- P/FCF- EPS past 5Y22.70% ROI-176.80% 52W High-95.07% Beta1.76
Dividend %- Quick Ratio0.90 Sales past 5Y-29.50% Gross Margin32.70% 52W Low13.80% ATR0.15
Employees13 Current Ratio0.90 Sales Q/Q50.00% Oper. Margin- RSI (14)36.22 Volatility5.31% 8.60%
OptionableNo Debt/Eq- EPS Q/Q76.40% Profit Margin- Rel Volume0.10 Prev Close0.74
ShortableYes LT Debt/Eq- EarningsMay 15 BMO Payout- Avg Volume871.73K Price0.74
Recom2.00 SMA20-5.00% SMA50-44.48% SMA200-88.04% Volume91,049 Change0.24%
Date Action Analyst Rating Change Price Target Change
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Jun-02-23 09:00AM
May-30-23 05:00AM
May-16-23 07:30AM
May-15-23 07:30AM
May-11-23 07:30AM
04:05PM Loading…
May-09-23 04:05PM
May-05-23 09:05AM
May-04-23 03:54PM
May-03-23 07:30AM
May-01-23 07:30AM
Apr-24-23 09:18AM
Apr-14-23 01:39PM
07:30AM Loading…
Apr-05-23 07:30AM
Apr-03-23 11:11AM
Mar-31-23 07:30AM
Mar-09-23 07:30AM
Feb-16-23 11:54AM
Feb-14-23 09:55AM
Feb-09-23 07:30AM
Jan-19-23 07:30AM
Jan-12-23 08:30AM
Jan-09-23 05:36AM
Dec-23-22 04:01PM
Dec-20-22 08:30AM
07:30AM Loading…
Dec-19-22 07:30AM
Dec-16-22 12:09PM
Dec-15-22 07:30AM
Dec-06-22 08:30AM
Nov-16-22 10:28AM
Nov-15-22 07:30AM
Nov-14-22 05:39AM
Nov-13-22 07:12AM
Nov-11-22 09:30AM
Nov-10-22 07:30AM
Nov-07-22 09:30AM
Oct-28-22 06:45AM
Oct-27-22 07:30AM
Oct-25-22 07:30AM
Oct-24-22 09:30AM
Oct-21-22 09:30AM
Oct-20-22 08:30AM
Oct-17-22 10:16AM
Oct-13-22 08:30AM
Sep-23-22 07:30AM
Sep-12-22 08:30AM
Sep-08-22 07:30AM
Sep-06-22 07:30AM
Aug-22-22 09:54AM
Aug-18-22 09:40AM
Aug-16-22 07:00AM
Aug-12-22 07:30AM
Jul-27-22 07:30AM
Jul-26-22 09:27AM
Jul-25-22 09:16AM
Jul-20-22 03:16PM
Jun-28-22 07:30AM
Jun-27-22 06:30AM
Jun-23-22 07:30AM
Jun-07-22 08:30AM
Jun-03-22 08:00AM
Jun-01-22 07:30AM
May-23-22 07:30AM
May-19-22 10:30AM
May-18-22 07:30AM
May-13-22 07:30AM
Apr-19-22 07:30AM
Mar-31-22 10:36AM
Mar-29-22 07:30AM
Mar-17-22 09:35AM
Mar-15-22 02:12PM
Mar-02-22 08:45AM
Mar-01-22 03:04PM
Feb-08-22 07:30AM
Jan-13-22 10:18AM
Jan-12-22 12:00PM
Jan-10-22 07:30AM
Jan-06-22 07:30AM
Jan-04-22 07:30AM
Dec-02-21 07:30AM
Nov-30-21 08:30AM
Nov-22-21 04:23AM
Nov-12-21 07:30AM
Nov-08-21 07:30AM
Nov-04-21 07:30AM
Nov-01-21 07:30AM
Oct-13-21 08:30AM
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.